Last reviewed · How we verify
Alleance®
Alleance® is an ophthalmic formulation designed to treat dry eye disease by lubricating and protecting the ocular surface.
Alleance® is an ophthalmic formulation designed to treat dry eye disease by lubricating and protecting the ocular surface. Used for Dry eye disease (keratoconjunctivitis sicca).
At a glance
| Generic name | Alleance® |
|---|---|
| Sponsor | Laboratorios Sophia S.A de C.V. |
| Drug class | Artificial tear / Ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Alleance® is a topical eye drop therapy that works as an artificial tear or ocular lubricant to relieve symptoms of dry eye disease. The formulation helps restore the tear film, reduce ocular surface inflammation, and provide sustained lubrication to the cornea and conjunctiva. It is intended for symptomatic relief and management of moderate to severe dry eye conditions.
Approved indications
- Dry eye disease (keratoconjunctivitis sicca)
Common side effects
- Ocular irritation
- Transient blurred vision
- Eye discomfort
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alleance® CI brief — competitive landscape report
- Alleance® updates RSS · CI watch RSS
- Laboratorios Sophia S.A de C.V. portfolio CI